Dr Eads on Nivolumab Plus Neoadjuvant Chemoradiation in Esophageal/GEJ Cancer

Jennifer R. Eads, MD, discusses neoadjuvant pCR rates with the addition of nivolumab to neoadjuvant chemoradiation in esophageal/GEJ cancer.

Jennifer R. Eads, MD, physician lead, GI Cancer Research, director, National Clinical Trials Network, Abramson Cancer Center, University of Pennsylvania, associate professor, clinical medicine (hematology-oncology), Penn Medicine, Perelman Center for Advanced Medicine, discusses the neoadjuvant pathologic complete response (pCR) rate results from the phase 2/3 ECOG-ACRIN EA2174 trial (NCT03604991) investigating the addition of nivolumab (Opdivo) to neoadjuvant chemotherapy and radiation in patients with locoregional esophageal and gastroesophageal junction (GEJ) adenocarcinoma.

Related Videos
Ahmad Tarhini, MD, PhD
Allison Winter, MD
Rocio Garcia-Carbonero, MD
Andrew Ip, MD
Anthony B. El-Khoueiry, MD
Daniel King, MD, PhD
Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study
Heinz-Josef Lenz, MD, FACP
Emrullah Yilmaz, MD, PhD
Marc-Oliver Grimm, MD